No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
GEM-CAP Sensitive: A2 - Guideline
|
GEM-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
VIP Sensitive: A2 - Guideline
|
VIP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CAP Sensitive: A2 - Guideline
|
CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CAP + prednisone Sensitive: A2 - Guideline
|
CAP + prednisone Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
ADOC Sensitive: A2 - Guideline
|
ADOC Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
pembrolizumab Resistant: A2 - Guideline
|
pembrolizumab Resistant: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
prednisone + octreotide Sensitive: A2 - Guideline
|
prednisone + octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
octreotide Sensitive: A2 - Guideline
|
octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
IGF1R expression
|
Thymoma
|
IGF1R expression
|
Thymoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
EIF4EBP1 expression
|
Thymoma
|
EIF4EBP1 expression
|
Thymoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
Thymoma
|
PD-L1 overexpression
|
Thymoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|